Teva Recalls Errin Norethindrone Tablets Due to Impurity Detection
Teva Pharmaceuticals is recalling Errin (norethindrone) tablets because an impurity called N-Butyl-Benzene Sulfonamide was detected during testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The agency classified this as FDA Class III, which is defined as unlikely to cause adverse health consequences. The hazard is a chemical impurity detected during testing, fitting the criteria for a moderate, precautionary recall.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 154,536 cartons of Errin (norethindrone tablets, USP), 0.35 mg. The product is a prescription-only medication used for a 28-day regimen. The recall covers specific lots distributed nationwide and in Puerto Rico.
The recall was initiated because an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing. This indicates a failure to meet impurity and degradation specifications. The affected lots have expiration dates ranging from July 2014 to June 2015.
Consumers and healthcare providers should check their inventory for the specific lot numbers listed in the recall notice. If the product matches the recalled lots, it should be returned to the pharmacy or supplier for disposal or replacement. No specific instructions for patient management are provided in the source text beyond the recall action.
The recalled product
- Product
- Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 154,536
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #s: 33801773A
- Exp 7/14
- 33801774A
- Exp 8/14
- 33801775A
- 33801776A
- Exp 9/14
- 33802427A
- 33802428A
- 33802429A
- 33802430A
- Exp 12/14
- 33802925A
- 33802926A
- Exp 3/15
- 33803383A
- 33803384A
- 33803385A
- 33803387A
- 33803685A
Distribution
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA, Inc.
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.2 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 30 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17